Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s expectations, but shares fell hard in after-hours trading, in an echo of Friday’s sell-off amid concerns about the fate of its Ozempic alternatives.